These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 12861225)

  • 1. Crystal structure of human cytochrome P450 2C9 with bound warfarin.
    Williams PA; Cosme J; Ward A; Angove HC; Matak Vinković D; Jhoti H
    Nature; 2003 Jul; 424(6947):464-8. PubMed ID: 12861225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple molecular dynamics simulations of human p450 monooxygenase CYP2C9: the molecular basis of substrate binding and regioselectivity toward warfarin.
    Seifert A; Tatzel S; Schmid RD; Pleiss J
    Proteins; 2006 Jul; 64(1):147-55. PubMed ID: 16639745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
    He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
    Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic regulation of warfarin metabolism and response.
    Daly AK; Aithal GP
    Semin Vasc Med; 2003 Aug; 3(3):231-8. PubMed ID: 15199455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based CoMFA as a predictive model - CYP2C9 inhibitors as a test case.
    Yasuo K; Yamaotsu N; Gouda H; Tsujishita H; Hirono S
    J Chem Inf Model; 2009 Apr; 49(4):853-64. PubMed ID: 19391630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing small-molecule binding to cytochrome P450 2D6 and 2C9: An in silico protocol for generating toxicity alerts.
    Rossato G; Ernst B; Smiesko M; Spreafico M; Vedani A
    ChemMedChem; 2010 Dec; 5(12):2088-101. PubMed ID: 21038340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study.
    Zhou YH; Zheng QC; Li ZS; Zhang Y; Sun M; Sun CC; Si D; Cai L; Guo Y; Zhou H
    Biochimie; 2006 Oct; 88(10):1457-65. PubMed ID: 16740353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P450 on drugs.
    Jabri E
    Nat Struct Biol; 2003 Aug; 10(8):587. PubMed ID: 12886290
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis.
    Sano E; Li W; Yuki H; Liu X; Furihata T; Kobayashi K; Chiba K; Neya S; Hoshino T
    J Comput Chem; 2010 Nov; 31(15):2746-58. PubMed ID: 20839301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative binding models for CYP2C9 based on benzbromarone analogues.
    Locuson CW; Rock DA; Jones JP
    Biochemistry; 2004 Jun; 43(22):6948-58. PubMed ID: 15170332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity.
    Flanagan JU; McLaughlin LA; Paine MJ; Sutcliffe MJ; Roberts GC; Wolf CR
    Biochem J; 2003 Mar; 370(Pt 3):921-6. PubMed ID: 12482324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.
    Ahlström MM; Ridderström M; Zamora I
    J Med Chem; 2007 Nov; 50(22):5382-91. PubMed ID: 17915853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of metabolism by cytochrome P450 2C9: alignment and docking studies of a validated database of substrates.
    Sykes MJ; McKinnon RA; Miners JO
    J Med Chem; 2008 Feb; 51(4):780-91. PubMed ID: 18237107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9.
    Peng CC; Rushmore T; Crouch GJ; Jones JP
    Bioorg Med Chem; 2008 Apr; 16(7):4064-74. PubMed ID: 18255300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AFM study of the interaction of cytochrome P450 2C9 with phospholipid bilayers.
    Nussio MR; Voelcker NH; Miners JO; Lewis BC; Sykes MJ; Shapter JG
    Chem Phys Lipids; 2010 Feb; 163(2):182-9. PubMed ID: 19925783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.
    He SM; Zhou ZW; Li XT; Zhou SF
    Curr Med Chem; 2011; 18(5):667-713. PubMed ID: 21182487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors.
    Ahlström MM; Ridderström M; Zamora I; Luthman K
    J Med Chem; 2007 Sep; 50(18):4444-52. PubMed ID: 17696334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of CYP2C9 inhibition by flavones and flavonols.
    Si D; Wang Y; Zhou YH; Guo Y; Wang J; Zhou H; Li ZS; Fawcett JP
    Drug Metab Dispos; 2009 Mar; 37(3):629-34. PubMed ID: 19074529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ethanol on S-warfarin and diclofenac metabolism by recombinant human CYP2C9.1.
    Tatsumi A; Ikegami Y; Morii R; Sugiyama M; Kadobayashi M; Iwakawa S
    Biol Pharm Bull; 2009 Mar; 32(3):517-9. PubMed ID: 19252308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.